Introduction {#s1}
============

*Acinetobacter baumannii* is dominant in clinical settings primarily targeting immunocompromised patients in intensive care units (ICUs) and has the potential to cause healthcare-associated infections ([@B1]). Infections caused by *A. baumannii* have repeatedly been reported to have grave clinical outcomes ([@B2], [@B3]). *A. baumannii* has an epidemic potential of emerging diseases because of its ability to persist in hospital environments by resisting desiccation and disinfectants ([@B1]). A propensity toward rapid acquisition of foreign DNA, including antimicrobial resistance determinants and virulence determinants, also contributes to its effective dissemination ([@B4]).

Previous studies have demonstrated that *A. baumannii* infections are accompanied by serious morbidity and mortality associated with a high sequential organ failure assessment (SOFA) score ([@B5]), comorbidities ([@B6]), immunosuppression ([@B3]), and antimicrobial treatment failure, mainly due to the multidrug resistance (MDR) of the causative *A. baumannii* ([@B5], [@B7], [@B8]). The rates of resistance to the major anti-*Acinetobacter* agents are increasing ([@B9]). In particular in South Korea, predominance of the multidrug-resistant international clonal lineage II (ICLII) in hospital settings is of great concern ([@B10]--[@B12]).

This study was performed to evaluate the possible clinical and bacteriologic features associated with 30-day mortality from *A. baumannii* bloodstream infection (BSI) for the entire 1-year incidence of *A. baumannii* BSI cases of multiple general hospitals in South Korea.

Methods {#s2}
=======

Study Design
------------

A prospective, multicenter, observational study was designed to monitor the entire *A. baumannii* BSI episodes between May 2016 and April 2017 occurring in six general hospitals with 715--1,050 beds participating in a national surveillance study of antimicrobial resistance in South Korea ([@B13]). Local ethics committee approvals were expedited or waived at each participating hospital since the study had a purely observational nature. The *A. baumannii* BSI cases were detected through reviewing daily blood culture results. One authorized investigator at each hospital reviewed patients\' medical records, all of the raw data were recorded in a pre-formatted spreadsheet, and the datasheet was submitted via email to an analysis center without monitoring. Prognoses of patients were followed for at least 30 days and the cases of transfer and hospital discharge were recorded as they were. The Charlson comorbidity index ([@B14]) and the SOFA score ([@B15]) were calculated in the analysis center using the collected raw data for the day of initial blood culture. For the sequential isolation of *A. baumannii* from one patient, the first isolate was used for analyses and the ensuing isolates were discarded. Among a total of 67,803 patients subjected to blood culture, *A. baumannii* isolates were recovered from blood specimens of 188 patients, and following the elimination of 7 episodes of death on the day of the initial blood culture, 181 cases were included in the analysis. The microbiological assessment was carried out in the analysis center.

Definitions
-----------

Laboratory-confirmed *A. baumannii* BSI was defined as an *A. baumannii*-positive blood culture from one or more blood specimens ([@B16]). Hospital-originated (HO) infection was specified by ≥2 calendar days of hospitalization at the day of initial blood culture, including the time spent at a previous health care facility before transfer. The 30-day mortality was defined as all-cause mortality within 30 days from the initial blood culture. Non-susceptibility (NS) to a drug class was defined as NS to at least one drug in a class and resistance phenotypes were categorized following Magiorakos et al. ([@B17]): MDR (NS to three or more drug classes), extensively drug resistance (XDR, NS to at least one agent in all but one or two drug classes), and pan-drug resistance (NS to at least one agent in all drug classes). An empirical antimicrobial therapy was defined as an initial antimicrobial treatment before the susceptibility testing results for the causative pathogen. A definitive antimicrobial therapy was defined as prescribing a revised antimicrobial regimen based on the antimicrobial susceptibility testing results and, if the revised regimen was administered after 72 h, it was deemed to be a delayed definitive therapy. Adequate antimicrobial therapy must include at least one antimicrobial agent active *in vitro* and both the dosage and route of administration should meet current medical standards.

Microbiological Assessment
--------------------------

Bacterial species were initially identified by matrix assisted laser desorption/ionization time-of-flight mass spectrometry using a Bruker Biotyper™ system (Billerica, MA, USA) and the detailed species of *Acinetobacter* spp. were confirmed by PCR and sequencing the *rpoB* gene. For *A. baumannii*, multilocus sequence typing was followed through the Oxford scheme ([@B18]). Antimicrobial susceptibility was tested following the Clinical and Laboratory Standards Institute (CLSI) guidelines ([@B19]). Antimicrobial susceptibilities to 13 anti-*Acinetobacter* agents belonging to seven drug classes were tested by the disk diffusion method. For carbapenem-resistant isolates, the *bla*~OXA−23~ gene and the IS*Aba1*-*bla*~OXA−51−like~ were identified by PCR and direct sequencing ([@B20]). Colistin MICs were determined by the broth microdilution method ([@B21]). Twenty-six virulence genes associated with eight virulence characteristics ([@B22]) were investigated by real-time PCR using gene-specific primers ([@B23]) and a KAPA SYBR Fast quantitative PCR master mix (Kapa biosystems, Inc., Wilmington, MA, USA). The resistance islands AbaR and AbGRI1 were specified by PCR using a set of primers, comMtr3_145-126F (5′-CAAGCGGTTGGCGTAAGACT-3′) and reverse primers tniB_546-525R (5′-CAAGTACATGCTCTGCAAGATG-3′) only for the full *tniB* gene and tniB_37-16R (5′-CAGACTCAATTCATTGCTGAGG-3′) for both the full and the truncated *tniB* genes.

Statistical Analysis
--------------------

Statistical analyses were performed in SPSS statistics (version 23, IBM Corp., Armonk, NY, USA). Data are expressed as the mean ± standard deviation if no special description is indicated. Categorical variables were compared by Pearson\'s X^2^ test, and continuous variables were compared by an independent two sample *t*-test. Associations between 30-day mortality and risk factors were evaluated using univariable and multivariable Cox proportional hazard regression models. The proportional hazards assumption was evaluated by including an interaction term between variables, and variables were natural-log transformed by follow-up time and by log-minus-log survival plots. For multivariable analyses, variables with a *P* value \<0.1 in univariable analyses were considered to include any possible variables. Multicollinearity between variables was diagnosed by calculating the variance inflation factors, and a multivariable analysis was conducted by the backward stepwise method. All tests of significance were two-tailed; *P* values \<0.05 were considered to be significant.

Results {#s3}
=======

Characteristics of Enrolled Patients
------------------------------------

A total of 181 laboratory-confirmed *A. baumannii* BSI cases were enrolled from the six participating hospitals and the number of cases was ranged from 22 to 52 by hospital ([Figure 1](#F1){ref-type="fig"}). Among patients with *A. baumannii* BSIs, the sex ratio of male *vs*. female was 115:66, and their mean age was 67.7 ± 14.3 years ([Table 1](#T1){ref-type="table"}). The mean Charlson comorbidity index score was 4.1 ± 2.2. Solid tumors (26.5%, 48/181), diabetes mellitus (23.2%, *n* = 42), cerebrovascular diseases (18.2%, *n* = 33), kidney diseases (13.8%, *n* = 25), and chronic pulmonary diseases (6.6%, *n* = 12) were the five most observed underlying diseases and dementia (*n* = 9) and chronic liver diseases (*n* = 7) were followed. Of the total, 88.4% (*n* = 160) of cases were HO infections, 95.0% (*n* = 172) were inpatients, and 68.0% of those (117/172) stayed in ICUs. The SOFA score had a mean value of 5.9 ± 3.5. Secondary BSIs were identified in 44.2% (80/181) of cases, and the majority (86.3%, 69/80) were originated from a pulmonary tract infection.

![Participating sentinel hospitals and collected *Acinetobacter baumannii* blood isolates. Locations of the hospitals (in gray) and covering parts (in gray patterns) are indicated in a map of the South Korean peninsula, respectively, and the associated table represent information regarding blood isolates from each hospital including demographic information from 2016. HO, hospital-origin; ICLII, international clonal lineage II; ST, sequence type.](fpubh-07-00233-g0001){#F1}

###### 

Thirty day mortality-associated factors for patients with an *Acinetobacter baumannii* BSI.

  **Variables**                                             **Total[^\*^](#TN1){ref-type="table-fn"}**   **Survival**    **30-day death[^†^](#TN2){ref-type="table-fn"}**   **P[^‡^](#TN3){ref-type="table-fn"}**   **Univariate model**     
  --------------------------------------------------------- -------------------------------------------- --------------- -------------------------------------------------- --------------------------------------- ------------------------ ---------
  **Demographic information**                                                                                                                                                                                                                
  Male                                                      115 (63.5%)                                  67 (64.4%)      48 (62.3%)                                         0.876                                   0.883 \[0.557--1.400\]   0.596
  Age                                                       67.7 ± 14.3                                  64.5 ± 15.5     72.1 ± 11.1                                        **\<0.001**                             1.033 \[1.014--1.054\]   \<0.001
  Inpatients                                                172 (95%)                                    98 (94.2%)      74 (96.1%)                                         0.735                                   1.355 \[0.427--4.298\]   0.606
  Hospital origin                                           160 (88.4%)                                  87 (83.7%)      73 (94.8%)                                         0.033                                   2.808 \[1.026--7.685\]   0.044
  Intensive care unit                                       117 (64.6%)                                  63 (60.6%)      54 (70.1%)                                         0.210                                   1.342 \[0.824--2.187\]   0.238
  **Underlying disease**[^¶^](#TN5){ref-type="table-fn"}                                                                                                                                                                                     
  Charlson index                                            4.1 ± 2.2                                    3.9 ± 2.2       4.4 ± 2.2                                          0.108                                   1.086 \[0.981--1.202\]   0.112
  Solid tumor                                               48 (26.5%)                                   27 (26.0%)      21 (27.3%)                                         0.866                                   1.183 \[1.109--1.261\]   \<0.001
  Diabetes mellitus                                         42 (23.2%)                                   28 (26.9%)      14 (18.2%)                                         0.213                                   0.049 \[0.000--7177\]    0.620
  Cerebrovascular disease                                   33 (18.2%)                                   23 (22.1%)      10 (13.0%)                                         0.125                                   0.597 \[0.307--1.161\]   0.129
  Kidney disease                                            25 (13.8%)                                   15 (14.4%)      10 (13.0%)                                         0.831                                   1.043 \[0.631--1.722\]   0.870
  Chronic pulmonary diseases                                12 (6.6%)                                    7 (6.7%)        5 (6.5%)                                           \>0.999                                 6.176 \[0.840--45.40\]   0.074
  Chronic liver diseases                                    7 (3.9%)                                     2 (1.9%)        5 (6.5%)                                           0.137                                   2.182 \[0.878--5.420\]   0.093
  Dementia                                                  9 (5.0%)                                     5 (4.8%)        4 (5.2%)                                           \>0.999                                 1.069 \[0.432--2.649\]   0.885
  Other[^\#^](#TN6){ref-type="table-fn"}                    5 (2.8%)                                     2 (1.9%)        3 (3.9%)                                           0.652                                   1.019 \[0.372--2.787\]   0.971
  **Severity variables**                                                                                                                                                                                                                     
  SOFA score                                                5.9 ± 3.5                                    4.8 ± 3.2       7.4 ± 3.5                                          **\<0.001**                             1.183 \[1.109--1.261\]   \<0.001
  **Lab data**                                                                                                                                                                                                                               
  WBC                                                       11.5 ± 7.8                                   12.2 ± 6.9      10.6 ± 8.8                                         0.185                                   0.967 \[0.934--1.000\]   0.052
  Hb                                                        10.4 ± 7.8                                   10.9 ± 10.4     9.6 ± 1.6                                          0.262                                   0.910 \[0.788--1.051\]   0.201
  Platelet                                                  169.7 ± 132.1                                206.9 ± 138.3   119.5 ± 104.8                                      **\<0.001**                             0.994 \[0.991--0.997\]   \<0.001
  **Origin of infection[^¶^](#TN5){ref-type="table-fn"}**                                                                                                                                                                                    
  Pulmonary tract                                           69 (38.1%)                                   36 (34.6%)      33 (42.9%)                                         0.281                                   1.259 \[0.801--1.978\]   0.317
  Wound                                                     7 (3.9%)                                     5 (4.8%)        2 (2.6%)                                           0.700                                   0.653 \[0.160--2.662\]   0.553
  Urinary tract                                             4 (2.2%)                                     4 (3.8%)        0 (0%)                                             0.138                                   0.048 \[0.000--18.92\]   0.319
  **Causative pathogen**                                                                                                                                                                                                                     
  Polymicrobial infection                                   44 (24.3%)                                   30 (28.8%)      14 (18.2%)                                         0.116                                   0.636 \[0.356--1.135\]   0.125
  ICLII[^††^](#TN7){ref-type="table-fn"}                    153 (84.5%)                                  83 (79.8%)      70 (90.9%)                                         0.060                                   2.083 \[0.958--4.533\]   0.064
  ST191 (1-3-3-2-2-94-3)                                    73 (40.3%)                                   29 (27.9%)      44 (57.1%)                                         **\<0.001**                             2.630 \[1.671--4.139\]   \<0.001
  ST784 (1-3-3-2-2-107-3)                                   31 (17.1%)                                   17 (16.3%)      14 (18.2%)                                         0.842                                   0.983 \[0.551--1.755\]   0.954
  ST451 (1-3-3-2-2-142-3)                                   29 (16.0%)                                   24 (23.1%)      5 (6.5%)                                           0.004                                   0.293 \[0.118--0.727\]   0.008
  **Virulence factors**                                                                                                                                                                                                                      
  Bacterial lipocalin, Blc                                  145 (80.1%)                                  79 (76.0%)      66 (85.7%)                                         0.132                                   1.540 \[0.813--2.916\]   0.185
  Pro-apoptotic porin, PorB                                 146 (80.7%)                                  79 (76.0%)      67 (87.0%)                                         0.086                                   1.839 \[0.946--3.575\]   0.073
  Small protein A, SmpA                                     177 (97.8%)                                  101 (97.1%)     76 (98.7%)                                         0.638                                   1.773 \[0.247--12.75\]   0.569
  Pili, Csu                                                 73 (40.3%)                                   45 (43.3%)      28 (36.4%)                                         0.363                                   0.781 \[0.491--1.243\]   0.297
  PNAG, Pga                                                 173 (95.6%)                                  96 (92.3%)      77 (100%)                                          0.022                                   22.02 \[0.307--1579\]    0.156
  Polysaccharide exporter, EpsA                             9 (5.0%)                                     7 (6.7%)        2 (2.6%)                                           0.305                                   0.425 \[0.104--1.730\]   0.232
  Capsule protein, MviM                                     7 (3.9%)                                     4 (3.8%)        3 (3.9%)                                           \>0.999                                 1.047 \[0.330--3.322\]   0.938
  Lipopolysaccharide, VipA                                  16 (8.8%)                                    9 (8.7%)        7 (9.1%)                                           \>0.999                                 1.021 \[0.469--2.220\]   0.959
  Lipopolysaccharide, Wzx                                   48 (26.5%)                                   26 (25%)        22 (28.6%)                                         0.613                                   1.144 \[0.698--1.875\]   0.595
  Glyconokinase, GntK                                       179 (98.9%)                                  102 (98.1%)     77 (100%)                                          0.508                                   20.54 \[0.004--93770\]   0.482
  Quorum Sensing, LuxR                                      159 (87.8%)                                  91 (87.5%)      68 (88.3%)                                         \>0.999                                 1.000 \[0.499--2.004\]   0.999
  Motility and secretion, PilA                              18 (9.9%)                                    12 (11.5%)      6 (7.8%)                                           0.460                                   0.723 \[0.314--1.664\]   0.446
  Siderophore, BasD                                         179 (98.9%)                                  102 (98.1%)     77 (100%)                                          0.508                                   20.54 \[0.004--93770\]   0.482
  **Antimicrobial resistance**                                                                                                                                                                                                               
  Penicillins NS                                            157 (86.7%)                                  82 (78.8%)      75 (97.4%)                                         **\<0.001**                             7.352 \[1.804--29.96\]   0.005
  3-, 4- gen. cephalosporins NS                             162 (89.5%)                                  85 (81.7%)      77 (100%)                                          **\<0.001**                             25.33 \[1.463--438.6\]   0.026
  Carbapenems NS                                            160 (88.4%)                                  84 (80.8%)      76 (98.7%)                                         **\<0.001**                             13.15 \[1.828--94.63\]   0.010
  Aminoglycosides NS                                        141 (77.9%)                                  76 (73.1%)      65 (84.4%)                                         0.073                                   1.515 \[0.818--2.805\]   0.187
  Fluoroquinolones NS                                       162 (89.5%)                                  85 (81.7%)      77 (100%)                                          **\<0.001**                             25.33 \[1.463--438.6\]   0.026
  Tetracyclines NS                                          13 (7.2%)                                    11 (10.6%)      2 (2.6%)                                           0.045                                   0.284 \[0.070--1.156\]   0.079
  Drug susceptible                                          18 (9.9%)                                    18 (17.3%)      0 (0%)                                             **\<0.001**                             0.040 \[0.002--0.743\]   0.031
  MDR/XDR                                                   162 (89.5%)                                  85 (81.7%)      77 (100%)                                          **\<0.001**                             25.33 \[1.463--438.6\]   0.026
  **Treatment**                                                                                                                                                                                                                              
  Adequate empirical therapy                                49 (27.1%)                                   30 (28.8%)      19 (24.7%)                                         0.613                                   0.744 \[0.443--1.249\]   0.263
  Definitive therapy within 72 h                            49 (27.1%)                                   39 (37.5%)      10 (13.0%)                                         **\<0.001**                             0.246 \[0.124--0.488\]   \<0.001

*The percentage was calculated from the total number of AB-BSI*.

*All-cause mortality within 30 days from the initial blood culture*.

*P value is either from Pearson\'s X^2^ test for categorical data or from the t-test for continuous data. Bonferroni corrected significance level from 32 hypotheses was considered to be P \<0.0016, and the significant P values are indicated in bold*.

*Cox proportional hazards regression model was applied to calculate the hazard ratio (HR) and the 95% confidence interval (CI)*.

*Underlying disease and primary site of infection could be multiple by patient*.

*Ulcer (n = 2), connective tissue disease (n = 2), congestive cardiac insufficiency (n = 2), and leukemia (n = 2) are included*.

*Multilocus sequence typing profiles are indicated with the combination of alleles (gltA-gyrB-gdhB-recA-cpn60-gpi-rpoD)*.

*SD, standard deviation; ICLII, the international clonal lineage II*.

The BSI-Causative *A. baumannii* Isolates
-----------------------------------------

### Sequence Types

The majority of the *A. baumannii* blood isolates belonged to ICLII (84.5%, 153/181) and the ICLII mostly comprised sequence type (ST) 191 (allele numbers of *gltA-gyrB-gdhB-recA-cpn60-gpi-rpoD*, 1-3-3-2-2-94-3; 47.7%, 73/153), ST784 (1-3-3-2-2-107-3; 20.3%, *n* = 31), and ST451 (1-3-3-2-2-142-3; 19.0%, *n* = 29). The 30-day mortality rate of patients with *A. baumannii* ICLII BSIs was 1.83-fold higher than that with *A. baumannii* BSIs by non-ICLII strains (45.8 vs. 25.0%); and among the ICLII BSIs, the 30-day mortality rate with ST191 BSIs was the highest and, the lowest for ST451 BSIs (60.3 vs. 17.2%).

### Antimicrobial Resistance

Majority of the *A. baumannii* blood isolates (89.5%, 162/181) were either MDR or XDR, and the proportion was markedly greater in *A. baumannii* ICLII (98.7%, 151/153; 18 MDR and 133 XDR) than in non-ICLII (39.3%, 11/28; 5 MDR, and 6 XDR). All of the tested isolates were susceptible to colistin, and no pan-drug resistant isolate was observed. All but one carbapenem-NS *A. baumannii* harbored the *bla*~OXA−23~ gene (99.4%, 159/160) and the remaining one carried an insertion sequence IS*Aba1* upstream from the *bla*~OXA−51−like~ gene. Two thirds and one-quarter of *A. baumannii* possessed AbGRI1 (63.0%, 114/181) and AbaR (26.5%, 48/181), respectively.

### Virulence Factors

Factors for adhesion and membrane integrity, biofilm formation, carbohydrate metabolism, quorum sensing, and siderophore were detected in *A. baumannii* blood isolates ([Table 1](#T1){ref-type="table"}). The acinetobactin-associated *basD* (98.9%, 179/181), the glycokinase *gntK* (98.9%, *n* = 179), the adhesion-associated *smpA* (97.8%, *n* = 177), and the biofilm formation-associated *pga* genes (95.6%, *n* = 173) were harbored by most of the *A. baumannii* blood isolates, while the capsule protein *mviM* (3.9%, *n* = 7), the polysaccharide exporter *epsA* (5.0%, *n* = 9), lipopolysaccharide *vipA* (8.8%, *n* = 16), and the type IV pili *pilA* (9.9%, *n* = 18) genes were occasionally identified. Among the virulence factors tested, the *pga* gene was significantly associated with 30-day death and the adhesion-associated *porB* had a tendency of 30-day mortality-associated.

A different frequency of each gene by ST was occasionally identified ([Table 2](#T2){ref-type="table"}). The *psaB* gene, formerly the *pab2* gene ([@B24]), was identified in all but one (96.6%, 28/29) ST451 isolates.

###### 

Characteristics of the *A. baumannii* ICLII blood isolates.

  **Characteristics**                      **ICLII**     ***P*[^\*^](#TN8){ref-type="table-fn"}**   **ST191**    ***P*[^\*^](#TN8){ref-type="table-fn"}**   **ST451**    ***P*[^\*^](#TN8){ref-type="table-fn"}**
  ---------------------------------------- ------------- ------------------------------------------ ------------ ------------------------------------------ ------------ ------------------------------------------
  Death within 30 days                     70 (45.8%)    0.002                                      44 (60.3%)   0.000                                      5 (17.2%)    0.013
  SOFA score (mean ± SD)                   5.9 ± 3.6     0.005                                      6.2 ± 3.9    0.031                                      6.4 ± 3.6    0.161
  Pulmonary tract of primary site of BSI   61 (39.9%)    0.000                                      24 (32.9%)   1.000                                      17 (58.6%)   0.002
  **Drug resistance**                                                                                                                                                    
  MDR/XDR                                  151 (98.7%)   0.821                                      72 (98.6%)   0.003                                      29 (100%)    0.545
  Penicillins NS                           146 (95.4%)   0.000                                      70 (95.9%)   0.000                                      27 (93.1%)   0.004
  3-, 4- gen. cephalosporins NS            151 (98.7%)   0.000                                      72 (98.6%)   0.000                                      29 (100%)    0.000
  Carbapenems NS                           149 (97.4%)   0.000                                      70 (95.9%)   0.000                                      29 (100%)    0.000
  Aminoglycosides NS                       136 (88.9%)   0.000                                      58 (79.5%)   0.006                                      29 (100%)    0.000
  Fluoroquinolones NS                      151 (98.7%)   0.000                                      72 (98.6%)   0.000                                      29 (100%)    0.000
  Tetracyclines NS                         11 (7.2%)     0.354                                      3 (4.1%)     0.553                                      6 (20.7%)    0.003
  Polymyxin                                0                                                        0                                                       0            
  **VIRULENCE FACTORS**                                                                                                                                                  
  **Drug resistance**                                                                                                                                                    
  AbGRI1 (Tn*6022*)                        112 (73.2%)   0.000                                      69 (94.5%)   0.000                                      5 (17.2%)    0.000
  AbaR (Tn*6019*)                          38 (24.8%)    0.164                                      2 (2.7%)     0.000                                      24 (82.8%)   0.000
  OXA-23                                   148 (96.7%)   0.000                                      70 (95.9%)   0.000                                      28 (96.6%)   0.001
  AdeC                                     32 (20.9%)    0.857                                      10 (13.7%)   0.110                                      6 (20.7%)    1.000
  **Adhesion/Membrane Integrity**                                                                                                                                        
  Blc                                      123 (80.4%)   0.002                                      56 (76.7%)   0.521                                      22 (75.9%)   1.000
  PorB                                     124 (81%)     0.000                                      64 (87.7%)   0.001                                      23 (79.3%)   0.505
  SmpA                                     149 (97.4%)   0.000                                      72 (98.6%)   0.002                                      27 (93.1%)   0.747
  **Biofilm formation**                                                                                                                                                  
  Csu                                      133 (86.9%)   0.000                                      62 (84.9%)   0.000                                      29 (100%)    0.000
  Pga                                      153 (100%)    0.000                                      73 (100%)    0.000                                      29 (100%)    0.002
  **Capsule protein**                                                                                                                                                    
  EpsA                                     7 (4.6%)      0.742                                      1 (1.4%)     0.107                                      3 (10.3%)    0.160
  MviM                                     6 (3.9%)      0.440                                      0 (0%)       0.099                                      2 (6.9%)     0.228
  **Lipopolysaccharide**                                                                                                                                                 
  PsaB                                     36 (23.5%)    0.000                                      2 (2.7%)     0.000                                      28 (96.6%)   0.000
  VipA                                     12 (7.8%)     0.448                                      7 (9.6%)     0.808                                      0 (0%)       0.084
  Wzx                                      42 (27.5%)    0.129                                      17 (23.3%)   0.869                                      10 (34.5%)   0.172
  **Carbohydrate metabolism**                                                                                                                                            
  GntK                                     153 (100%)    0.000                                      73 (100%)    0.000                                      29 (100%)    0.003
  **Quorum sensing system**                                                                                                                                              
  LuxR                                     138 (90.2%)   0.000                                      65 (89%)     0.175                                      27 (93.1%)   0.183
  **Motility and secretion**                                                                                                                                             
  PilA                                     14 (9.2%)     0.808                                      2 (2.7%)     0.015                                      5 (17.2%)    0.164
  **Siderophore**                                                                                                                                                        
  BasD                                     153 (100%)    0.000                                      73 (100%)    0.000                                      29 (100%)    0.010
  **Treatment**                                                                                                                                                          
  Adequate empirical therapy               31 (20.3%)    0.000                                      16 (21.9%)   0.003                                      3 (10.3%)    0.002
  Definitive therapy within 72 h           46 (30.1%)    0.013                                      20 (27.4%)   0.624                                      11 (37.9%)   0.109

*P value is either from Pearson\'s X^2^ test for categorical data or from the t-test for continuous data. The Bonferroni corrected significance level from 33 hypotheses was considered to be P \< 0.0015, and the significant P values are indicated with asterisks*.

### Antimicrobial Treatment

The majority (95.0%, 172/181) of patients with *A. baumannii* BSIs received an empirical antimicrobial therapy with anti-*Acinetobacter* drugs and 28.5% (49/172) of those were adequate ([Table 3](#T3){ref-type="table"}). The other nine patients received either not-for-*Acinetobacter* drugs (*n* = 7) or none due to refusal of treatment (*n* = 2). Among the 132 patients who received an inadequate empirical therapy, 37.1% (*n* = 49) of patients were treated with a definitive antimicrobial therapy within 72 h and 20.4% (10/49) of those patients met death within 30 days, much less than that of patients who received a delayed definitive therapy (57.9%, 48/83).

###### 

Antimicrobial regimens for the patients with *A. baumannii* BSIs.

  **Regimen**                                    **No. of**   **cases**   **Proper**   **Improper**
  ---------------------------------------------- ------------ ----------- ------------ --------------
  Ampicillin                                     1            0.6%        1            0
  Pipercillin/tazobactam                         26           14.4%       5            21
  comb.w/ciprofloxacin                           12           6.6%        1            11
  comb.w/tigecycline                             2            1.1%        1            1
  comb.w/colistin                                2            1.1%        2            0
  3-, 4- gen. cephalosporins                     20           11.0%       5            15
  comb.w/ciprofloxacin                           8            4.4%        0            8
  comb.w/aminoglycosides                         2            1.1%        0            2
  Carbapenems                                    55           30.4%       5            50
  comb.w/aminoglycosides                         2            1.1%        0            2
  comb.w/co-trimoxazole                          2            1.1%        1            1
  comb.w/ciprofloxacin                           9            5.0%        1            8
  comb.w/colistin                                10           5.5%        10           0
  Tigecycline                                    6            3.3%        5            1
  comb.w/co-trimoxazole                          1            0.6%        1            0
  comb.w/fluoroquinolones                        2            1.1%        2            0
  Colistin                                       4            2.2%        4            0
  Ciprofloxacin                                  6            3.3%        4            2
  Aminoglycosides                                1            0.6%        0            1
  Co-trimoxazole                                 1            0.6%        1            0
  Not treated[^\*^](#TN9){ref-type="table-fn"}   9            5.0%        0            9
                                                 181                      49           132

*Patients received drugs not-for-Acinetobacter (n = 7) or none due to refusal of treatment (n = 2)*.

### Risk Factors for 30-Day Mortality

Risk and protective factors associated with the 30-day mortality in patients with *A. baumannii* BSIs were searched for among the variables of *P* \<0.1 through a Cox-regression univariable analysis. Most of the variables were omitted by stepwise selection procedure, and each three of risk factors and protective factors associated with the 30-day mortality in patients with *A. baumannii* BSIs were identified through a Cox-regression multivariable analysis ([Table 4](#T4){ref-type="table"}): the age of patients of hazard ratio (95% CI), 1.033 (1.010--1.056); the SOFA score of 1.133 (1.041--1.233); and the BSI-causative *A. baumannii* ST191 of 1.918 (1.073--3.430). Three protective factors were also identified: the platelet count of 0.996 (0.993--0.999), the BSI-causative *A. baumannii* ST451 of 0.228 (0.078--0.672), and the definitive therapy within 72 h of 0.255 (0.125--0.519).

###### 

Risk factors associated with the 30-day mortality in patients with *A. baumannii* BSI.

  **Variables**                    **VIF[^\*^](#TN10){ref-type="table-fn"}**   **HR \[95%CI\][^†^](#TN11){ref-type="table-fn"}**   ***P***
  -------------------------------- ------------------------------------------- --------------------------------------------------- ---------
  Age                              1.058                                       1.033 \[1.010--1.056\]                              0.005
  SOFA score                       1.335                                       1.133 \[1.041--1.233\]                              0.004
  Platelet                         1.290                                       0.996 \[0.993--0.999\]                              0.016
  ST191                            1.245                                       1.918 \[1.073--3.430\]                              0.028
  ST451                            1.255                                       0.228 \[0.078--0.672\]                              0.007
  Definitive therapy within 72 h   1.094                                       0.255 \[0.125--0.519\]                              \<0.001

*VIF, variance inflation factor. The collinearity was diagnosed for the variables including the multivariate analysis*.

*A Cox-regression multivariate analysis was conducted by the backward method using the Wald model*.

Discussion {#s4}
==========

During the surveillance study period, the overall incidence of *A. baumannii* was the third-highest (1.1/10,000 patient-days) BSI-causative Gram-negative bacteria followed by *Escherichia coli* and *Klebsiella pneumoniae*. Besides, the incidence was strikingly higher in ICUs (6.6/10,000 patient-days) than in general wards (0.4/10,000 patient-days) ([@B25]). The 30-day mortality rate of patients with *A. baumannii* BSIs is pretty varied by study depending on the subjected patients, and we observed 42.5% of 30-day mortality for entire *A. baumannii* BSI cases.

Among the variables studied, the old age and the high SOFA score were identified as the patient-associated risk factors. Those were reasonable hazardous factors since both factors pronounced the severity of illness directly or indirectly. A patient-associated protective factor, platelet counts in peripheral blood reflecting the patients\' condition also made sense. As well, a treatment-associated protective factor, a proper definitive therapy within 72 h was comprehensible.

Curiously among the causative-pathogen-associated variables, the *A. baumannii* ST191 was a risk factor, while the ST451, another ICLII member, was a protective factor. *A. baumannii* ICLII, is a well-known multidrug resistant clone ([@B26], [@B27]). The treatment options for patients infected by the clone are often limited to the very last resorts, such as carbapenems, tigecycline, minocycline, and polymyxins. For the infections cause by multidrug-resistant *A. baumannii*, the use of combination antimicrobial therapy is recommended ([@B28]) and two thirds (66.3%, 120/181) of the patients were treated empirically by antimicrobial combinations. Carbapenem resistance is already common in ICLII, and the remaining choices are always risky because tigecycline ([@B29]) and minocycline ([@B30]) have a bacteriostatic activity, which requires a combinational treatment; colistin has a severe dose-dependent neuro- and nephrotoxicity ([@B31]); and the colistin resistance is easily developed by prior use of the drug ([@B32]). The importance of an adequate antimicrobial therapy ([@B33]), including the proper use of colistin ([@B34]), has been addressed to diminish the 30-day mortality rate caused by *A. baumannii* infections. The present results confirmed the notion through a significant protective effect of the definitive therapy including colistin. Among ICLII members, ST191 was the most and both ST784 and ST451 are recently emerging ICLII clones ([@B27], [@B32]). In this study, ST784 and ST451 were the second and third most ICLII clones and the clones were evenly recovered from the six hospitals ([Figure 2](#F2){ref-type="fig"}).

![Mortality of BSI patients by causative pathogen. **(A)** Mortality of patients with BSIs by *A. baumannii*, **(B)** comparison of mortality of BSI patients by ICLII and by non-ICLII *A. baumannii*, **(C)** comparison of mortality of BSI patients by ST191, ST451, and other STs belonging to CC91. The Kaplan-Meier plot illustrated survival in patients with AB-BSI infected with the indicated bacterial clone. Differences between groups were compared by the Log-Rank test of the Mantel-Cox model, and the *P* values are presented. ICLII, international clonal lineage II; ST, sequence type.](fpubh-07-00233-g0002){#F2}

In this study, all but two (98.7%) ICLII blood isolates, one ST191 and the other ST357, exhibited MDR/XDR. Since drug resistance is one of the noted hazardous factors obstructing an adequate antimicrobial therapy ([@B7], [@B8]), similar mortality rates were presumed for BSIs caused by any STs belonging to the ICLII. However, a marked difference in 30-day mortality was observed in the three dominant STs: 60.3% in ST191 BSIs, 45.2% in ST784 BSIs, and 17.2% in ST451 BSIs. Curiously, the least proportion of patients with ST451 BSIs (10.3%) were treated by an adequate empirical therapy ([Table 2](#T2){ref-type="table"}), indicating that the drug resistance and the relevant adequacy of treatment were not related to the 30-day mortality rate at least to BSIs caused by ST191 and ST451. ST451 was more associated with a primary pulmonary tract infection (58.6%) than ST191 (32.9%), however the primary site of infection was insignificantly associated with a 30-day death ([Table 1](#T1){ref-type="table"}). Similarly, ST451 harbored the Tn*6019*-associated AbaR (82.8%) more frequently than the Tn*6022*-associated AbGRI1 (17.2%) differently from ST191 (2.7 vs. 94.5%), however no difference was expected since both may harbor the *bla*~OXA−23~ gene ([@B12]). The lipooligosaccharide biosynthesis-associated *psaB* gene was harbored strikingly more by ST451 than by ST191 (96.6 vs. 2.7%). The *psaB* gene is a part of the oligosaccharide gene clusters generating an ordinary side-branch sugar Gal, differing from the *A. baumannii* ST191 often carries the gene cluster producing FucNAc sugar composing the oligosaccharide ([@B24]). Since the lipooligosaccharides of pathogenic bacteria have long been recognized as a major virulence factor ([@B35]), the difference in oligosaccharides between the two clones is possibly associated with the 30-day mortality rate and the detailed impact should be further studied.

This study should be considered with the following caveats in mind. First, the enrolled cases had a lack of external validation due to a distinct epidemiology of *A. baumannii* clinical isolates in South Korea in terms of high carbapenem resistance, mostly conferred by OXA-23. Second, analyses of bacterial lipooligosaccharides differed by the clones are remained for further study. However, to the best of our knowledge, this is the first notification of the counter clinical prognoses of the patients with a BSI by dominant ICLII clones, drawing an attention to a further follow-up for the clonal exchange and expansion of ICLII clones in clinical settings.

This delicate prognosis assessment combined with an evaluation of the molecular epidemiology for the causative *A. baumannii* blood isolates confirmed (i) the predominance of ICLII in clinical settings, (ii) the hazardousness of antimicrobial resistance and the importance of an adequate antimicrobial therapy, and finally, (iii) we highlighted the differing 30-day mortality rates in patients with BSIs between causative multidrug-resistant *A. baumannii* clones ST191 and ST451 belonging ICLII probably due to the differing lipooligosaccharides.
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